Fifty-five geriatric outpatients with insomnia were treated for four consecutive nights in a placebo-controlled double-blind study to assess the safety and efficacy of a new modified triazolo-diazepine, brotizolam. Nightly therapy was 0.125 mg brotizolam, a smaller dose than in previous adult studies. Compared to placebo, brotizolam exhibited statistically significant efficacy in most items measured by patient questionnaires and physician evaluations. More patients receiving brotizolam judged their response as satisfactory and would continue this medication if indicated in comparison with placebo. Physician's assessments revealed that 71% of brotizolam-treated patients reported at least some improvement of their insomnia, but only 19% of patients on placebo observed some relief. Daytime drowsiness was more frequently reported as a side effect by patients in the brotizolam-treated group.
|Original language||English (US)|
|Number of pages||9|
|Journal||Current Therapeutic Research - Clinical and Experimental|
|State||Published - Jan 1 1986|
ASJC Scopus subject areas
- Pharmacology (medical)